share_log

Maxim Group Initiates Coverage On Belite Bio With Buy Rating, Announces Price Target of $60

Benzinga ·  Dec 14, 2023 22:11

Maxim Group analyst Jason McCarthy initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $60.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment